Metraipolis › archive › dc_b2fb76df759b

Efficacy and safety of [161Tb]Tb-PSMA radioligand therapy in metastatic castration resistant prostate cancer: a systematic review and meta-analysis — Europe PMC PMID:42620854

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42620854
DOI
10.3389/fmed.2026.1925657
License (as archived)
solo-consultazione
Archived
2026-10-17T01:37:06.140Z
SHA-256 of the archived text
faf8c0a9c24700d2bf3d820837bfd742606f6337889ee3d27a4625a1ff5196f1
Stable URL of this page
https://metraipolis.com/documento/dc_b2fb76df759b

How to cite

Efficacy and safety of [161Tb]Tb-PSMA radioligand therapy in metastatic castration resistant prostate cancer: a systematic review and meta-analysis — Europe PMC PMID:42620854 — Europe PMC (en), https://europepmc.org/article/MED/42620854 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b2fb76df759b (Metraipolis archive dc_b2fb76df759b, sha256 faf8c0a9c24700d2bf3d820837bfd742606f6337889ee3d27a4625a1ff5196f1)
BibTeX
@misc{dcb2fb76df759b,
  title = {Efficacy and safety of [161Tb]Tb-PSMA radioligand therapy in metastatic castration resistant prostate cancer: a systematic review and meta-analysis — Europe PMC PMID:42620854},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42620854},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b2fb76df759b; sha256 faf8c0a9c24700d2bf3d820837bfd742606f6337889ee3d27a4625a1ff5196f1},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42620854. Agents can read the archived copy with the MCP tool read_document.